vida: extract claims from 2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap

- Source: inbox/queue/2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The evidence base for GLP-1 effects in restrictive eating disorders is entirely theoretical and mechanistic with no clinical trial data, creating a regulatory and clinical knowledge gap
+confidence: proven
+source: MDPI Nutrients review confirming 'extremely limited' AN evidence; VigiBase aROR 4.17-6.80
+created: 2026-05-04
+title: No RCT evidence exists for GLP-1 receptor agonists in anorexia nervosa despite pharmacovigilance signals showing 4-7x elevated eating disorder risk
+agent: vida
+sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md
+scope: structural
+sourcer: MDPI Nutrients
+supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks"]
+---
+
+# No RCT evidence exists for GLP-1 receptor agonists in anorexia nervosa despite pharmacovigilance signals showing 4-7x elevated eating disorder risk
+
+This review explicitly confirms that evidence for GLP-1 receptor agonists in anorexia nervosa (AN) is 'extremely limited' with theoretical risks rather than empirical data. The paper states that risks for restrictive eating disorders include 'appetite suppression masking restrictive behaviors, compulsive reliance on medication for control, reinforcement of maladaptive food rules' but provides no RCT citations for these outcomes. This creates a critical evidence gap: pharmacovigilance systems show elevated eating disorder risk (VigiBase aROR 4.17-6.80), clinical guidelines recommend pre-treatment eating disorder screening, yet no prospective trials have tested GLP-1 safety or efficacy in patients with restrictive eating disorder histories. The absence of trial evidence means that current prescribing occurs without subtype-specific risk stratification. The review notes that benefits for BED (reduced binge episodes) 'may not persist long-term,' suggesting that even for the eating disorder subtype with positive theoretical rationale, durability is uncertain. This evidence vacuum is particularly concerning given that the review recommends 'rigorous monitoring until long-term safety in diverse populations established' while acknowledging that such monitoring infrastructure does not currently exist in standard prescribing practice.

domains/health/glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
 scope: correlational
 sourcer: Truveta Research
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
 ---
 
 # GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence
@@ -24,3 +24,10 @@ Truveta's analysis of real-world GLP-1 discontinuation patterns found that patie
 **Source:** VigiBase study, Clinical Nutrition 2025
 
 Concurrent prescribing analysis shows OR 4.45 for suicidal ideation reports with antidepressants and OR 4.07 with benzodiazepines. The highest-risk patients are those with pre-existing psychiatric pharmacotherapy, creating a safety-persistence paradox: the patients most likely to discontinue (psychiatric comorbidity) are also those with highest adverse event reporting rates.
+
+
+## Extending Evidence
+
+**Source:** MDPI Nutrients PMC12694361
+
+Review identifies eating disorder history, perfectionism, OCD traits, and emotion regulation deficits as primary risk factors for GLP-1 adverse psychiatric outcomes. This extends the psychiatric comorbidity discontinuation pattern by specifying which psychiatric phenotypes create highest risk: restrictive eating disorders and obsessive-compulsive spectrum conditions rather than psychiatric comorbidity in general.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The same GLP-1R-mediated appetite suppression that reduces binge episodes in BED via mesolimbic dopamine modulation can reinforce restriction behaviors in anorexia nervosa and atypical AN by enhancing satiety in vulnerable individuals
+confidence: experimental
+source: MDPI Nutrients review, PMC12694361
+created: 2026-05-04
+title: "GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism"
+agent: vida
+sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md
+scope: causal
+sourcer: MDPI Nutrients
+supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
+---
+
+# GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism
+
+This review establishes that GLP-1 receptor agonists create opposing clinical outcomes across eating disorder subtypes through a single pharmacological mechanism. For binge eating disorder (BED), GLP-1 RAs reduce binge episodes by modulating mesolimbic dopamine circuits that drive reward-based eating. However, for restrictive eating disorders (anorexia nervosa, atypical AN), the same appetite suppression mechanism that benefits BED patients can reinforce existing restriction patterns by enhancing satiety signals in individuals already predisposed to under-eating. The paper notes that evidence for anorexia nervosa is 'extremely limited' with theoretical risks including 'appetite suppression masking restrictive behaviors' and 'reinforcement of maladaptive food rules.' This creates a clinical paradox where the drug's core mechanism of action is therapeutic for one eating disorder subtype and potentially iatrogenic for another. The review identifies highest-risk populations as individuals with restrictive eating disorder histories, those with high perfectionism or OCD traits, adolescents during critical development, and racial/ethnic minorities facing intersectional stigma. This mechanistic framework explains the VigiBase pharmacovigilance signal (aROR 4.17-6.80 for eating disorders) by showing that aggregate eating disorder risk masks subtype-specific directionality.

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Clinical recommendations for SCOFF questionnaire screening and monitoring of eating behaviors exist in academic literature but have not been adopted into mandatory prescribing protocols
+confidence: proven
+source: MDPI Nutrients review recommendations; absence from FDA labeling and professional society guidelines
+created: 2026-05-04
+title: Pre-treatment eating disorder screening is recommended by clinical reviews but not required by any professional guideline or regulatory body despite 4-7x elevated pharmacovigilance risk
+agent: vida
+sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md
+scope: structural
+sourcer: MDPI Nutrients
+supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+---
+
+# Pre-treatment eating disorder screening is recommended by clinical reviews but not required by any professional guideline or regulatory body despite 4-7x elevated pharmacovigilance risk
+
+This review provides detailed clinical recommendations for eating disorder risk mitigation: (1) pre-treatment screening using SCOFF questionnaire for eating disorder history, compensatory behaviors, body image, and emotion regulation; (2) ongoing monitoring of eating behaviors, mood, and suicidal ideation with heightened vigilance during dose escalations; (3) multidisciplinary approach with psychological care, dietitian, and medical oversight rather than standalone medication; (4) preventive strategies introducing DBT/mindfulness before appetite suppression eliminates food-based coping. However, these recommendations exist only in academic literature. No FDA labeling requirement mandates eating disorder screening before GLP-1 initiation. No professional society guideline (Endocrine Society, Obesity Medicine Association, ADA) requires SCOFF or equivalent screening as a prescribing precondition. The review concludes that GLP-1s 'must be approached with caution: integrated into multidisciplinary care with rigorous monitoring' but this integration is aspirational rather than operationalized. This creates a gap between evidence-based risk mitigation and actual prescribing practice, particularly concerning given that 92 percent of GLP-1 users receive no dietitian support (per existing KB claim) and the review identifies eating disorder history as a primary risk factor requiring specialist oversight.

domains/health/glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations.md

@@ -10,9 +10,16 @@ agent: vida
 sourced_from: health/2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions.md
 scope: causal
 sourcer: Clinical Trial Vanguard
-related: ["clinical-ai-bias-amplification-creates-compounding-disparity-risk-at-scale", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
+related: ["clinical-ai-bias-amplification-creates-compounding-disparity-risk-at-scale", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism"]
 ---
 
 # GLP-1 psychiatric effects are directionally opposite in metabolic versus psychiatric disease patients — protective in metabolic cohorts but potentially harmful in severe psychiatric comorbidity with concurrent psychotropic use
 
 The GLP-1 psychiatric safety paradox resolves through population stratification rather than dismissing either signal. Clinical trials and cohort studies systematically exclude patients with 'psychiatric instability' — specifically those with substance use disorders, prior mood episodes, or active anhedonia. This creates a bifurcated evidence base: (1) Trial/cohort populations over-represent metabolically driven psychiatric patients where GLP-1 appears protective (Swedish cohort showing reduced depression/anxiety in metabolic disease context), and (2) Pharmacovigilance captures real-world deployment including psychiatric comorbidity patients where GLP-1 may worsen symptoms. The highest-risk subpopulation is patients on concurrent psychotropic medications (antidepressants, benzodiazepines) showing OR 4.07-4.45 for suicidality reporting. The Novo Nordisk semaglutide MDD program (interim data late 2026) will provide the first prospective RCT evidence in psychiatric patients rather than metabolic patients with psychiatric comorbidities, serving as the decisive test of whether GLP-1 is genuinely antidepressant or whether the metabolic patient finding is a selection effect. The eating disorder signal is consistent with this framework: GLP-1 appetite suppression may trigger pathology in vulnerable patients systematically excluded from trials but present in real-world deployment.
+
+
+## Challenging Evidence
+
+**Source:** WHO guideline 2025-12-01, absence of psychiatric contraindications
+
+WHO guideline excludes only pregnant women as explicit contraindication, with no mention of psychiatric comorbidity screening despite documented eating disorder signal (aROR 4.17-6.80) and evidence that psychiatric populations show different response patterns. This suggests regulatory guidance has not incorporated psychiatric population stratification.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
 scope: causal
 sourcer: PubMed/ClinicalTrials.gov systematic review
 challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
-related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients"]
 supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery"]
 reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24"]
 ---
@@ -102,3 +102,10 @@ Meta-analysis of 5.26M patients across 14 studies shows 28-36% reduction in AUD-
 **Source:** SEMALCO trial, The Lancet 2026
 
 SEMALCO Phase 2 RCT (N=108, 26 weeks) showed semaglutide 2.4mg reduced heavy drinking days 41% vs 26% placebo (p=0.0015) with NNT=4.3, outperforming all approved AUD medications (NNT≥7). Blood-alcohol biomarkers objectively confirmed self-report. Secondary finding: greater cigarette reduction in concurrent users suggests GLP-1 acts across reward circuits simultaneously, supporting mesolimbic dopamine mechanism rather than AUD-specific pathway.
+
+
+## Extending Evidence
+
+**Source:** MDPI Nutrients PMC12694361
+
+Review confirms that GLP-1 RAs reduce binge eating disorder episodes through mesolimbic dopamine modulation, the same mechanism that produces alcohol and substance use disorder benefits. However, it notes that this mechanism creates opposing outcomes for restrictive eating disorders, establishing that mesolimbic dopamine modulation is not universally therapeutic across all reward dysregulation conditions.

domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md

@@ -10,12 +10,17 @@ agent: vida
 scope: structural
 sourcer: Health Policy Watch
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"]
-supports:
-- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
-reweave_edges:
-- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes|supports|2026-04-07
+supports: ["Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes"]
+reweave_edges: ["Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes|supports|2026-04-07"]
+related: ["regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence", "regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence", "eu-ai-act-medical-device-simplification-shifts-burden-from-requiring-safety-demonstration-to-allowing-deployment-without-mandated-oversight", "regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence", "clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance"]
 ---
 
 # Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
 
-The simultaneous release of the EU Commission's proposal to ease AI Act requirements for medical devices and WHO's explicit warning of 'heightened patient risks due to regulatory vacuum' documents a regulator-vs.-regulator split at the highest institutional level. The Commission proposed postponing high-risk AI requirements by up to 16 months and potentially removing them entirely for medical devices, arguing industry concerns about 'dual regulatory burden.' The same week, WHO warned that requirements for technical documentation, risk management, human oversight, and transparency would no longer apply by default to AI medical devices, creating a regulatory vacuum where 'clinicians will still be expected to use AI safely and manage edge cases, yet the regulatory system will no longer guarantee that systems are designed to support meaningful human oversight.' This is qualitatively different from industry-research tension or academic debate—it represents institutional epistemic divergence where the body responsible for patient safety (WHO) directly contradicts the body responsible for regulation (EU Commission). The Commission's proposal appears to have been developed without reference to WHO's safety evidence or the research literature on clinical AI failure modes, suggesting these institutions are operating in genuinely different epistemic frameworks—one accumulating safety evidence, the other responding to industry lobbying on regulatory burden.
+The simultaneous release of the EU Commission's proposal to ease AI Act requirements for medical devices and WHO's explicit warning of 'heightened patient risks due to regulatory vacuum' documents a regulator-vs.-regulator split at the highest institutional level. The Commission proposed postponing high-risk AI requirements by up to 16 months and potentially removing them entirely for medical devices, arguing industry concerns about 'dual regulatory burden.' The same week, WHO warned that requirements for technical documentation, risk management, human oversight, and transparency would no longer apply by default to AI medical devices, creating a regulatory vacuum where 'clinicians will still be expected to use AI safely and manage edge cases, yet the regulatory system will no longer guarantee that systems are designed to support meaningful human oversight.' This is qualitatively different from industry-research tension or academic debate—it represents institutional epistemic divergence where the body responsible for patient safety (WHO) directly contradicts the body responsible for regulation (EU Commission). The Commission's proposal appears to have been developed without reference to WHO's safety evidence or the research literature on clinical AI failure modes, suggesting these institutions are operating in genuinely different epistemic frameworks—one accumulating safety evidence, the other responding to industry lobbying on regulatory burden.
+
+## Supporting Evidence
+
+**Source:** WHO guideline 2025-12-01
+
+WHO issued global GLP-1 obesity guideline in December 2025 without eating disorder screening requirements despite pharmacovigilance signal (aROR 4.17-6.80) documented in literature 18+ months prior. Regulatory expansion occurred without integrating known safety signals into prescribing infrastructure.

domains/health/who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap.md

@@ -10,7 +10,7 @@ agent: vida
 scope: structural
 sourcer: WHO
 supports: ["glp-1-access-structure-inverts-need-creating-equity-paradox"]
-related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap", "who-glp1-conditional-endorsement-signals-system-readiness-gap", "who-glp1-behavioral-supplement-low-certainty-evidence"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap", "who-glp1-conditional-endorsement-signals-system-readiness-gap", "who-glp1-behavioral-supplement-low-certainty-evidence", "who-glp1-conditional-recommendation-reflects-structural-access-barriers-not-clinical-efficacy-uncertainty"]
 ---
 
 # WHO endorsed GLP-1s for obesity treatment in December 2025 while USPSTF maintains its 2018 recommendation excluding pharmacotherapy creating the largest international-US preventive coverage policy gap in modern history
@@ -29,3 +29,10 @@ The WHO's 'conditional' framing (versus 'strong' recommendation) acknowledges co
 **Source:** WHO Global Guideline, December 2025
 
 WHO issued conditional recommendation December 2025 with explicit equity and access concerns, while USPSTF maintains 2018 exclusion. The WHO conditionality is based on 'high current costs' and 'inadequate health system readiness' which directly impacts ACA mandatory coverage pathway that depends on USPSTF grade A or B recommendation
+
+
+## Extending Evidence
+
+**Source:** WHO news release 2025-12-01
+
+WHO December 2025 guideline is a conditional recommendation citing 'limited data on long-term efficacy and safety' and concerns about 'falsified and substandard medical products' requiring 'regulated distribution and prescription by qualified health care providers.' The conditional nature suggests WHO recognizes infrastructure gaps beyond clinical efficacy.

domains/health/who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Regulatory response gap where signal magnitude (aROR 4.17-6.80, highest psychiatric signal) is disproportionate to regulatory action (none)
+confidence: experimental
+source: WHO guideline news release 2025-12-01, VigiBase eating disorder signal literature 2024-2025
+created: 2026-05-04
+title: WHO December 2025 GLP-1 obesity guideline contains no eating disorder screening requirement despite pharmacovigilance signal predating guideline by 18+ months
+agent: vida
+sourced_from: health/2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap.md
+scope: structural
+sourcer: World Health Organization
+supports: ["regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence"]
+related: ["healthcare-ai-regulation-needs-blank-sheet-redesign-because-the-fda-drug-and-device-model-built-for-static-products-cannot-govern-continuously-learning-software", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "who-glp1-conditional-endorsement-signals-system-readiness-gap", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "who-glp1-conditional-recommendation-reflects-structural-access-barriers-not-clinical-efficacy-uncertainty", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap"]
+---
+
+# WHO December 2025 GLP-1 obesity guideline contains no eating disorder screening requirement despite pharmacovigilance signal predating guideline by 18+ months
+
+The WHO issued a global guideline on December 1, 2025, recommending GLP-1 receptor agonists (semaglutide and two other agents) for long-term obesity treatment in adults. The guideline news release identifies only one explicit population exclusion: pregnant women. No eating disorder contraindications, screening requirements, or psychiatric adverse event profile discussion appears in the release. The guideline cites 'limited data on their long-term efficacy and safety' as rationale for conditional recommendation, but eating disorders are not specifically named among safety concerns requiring more data. This represents a regulatory response gap: the VigiBase pharmacovigilance eating disorder signal (aROR 4.17-6.80, documented in literature throughout 2024-2025) predated this guideline by at least 18 months, yet no screening infrastructure was mandated. The contrast is stark when compared to the suicidality signal (aROR 1.45), which received formal FDA/EMA review in January 2026 despite lower magnitude. The eating disorder signal represents the highest psychiatric adverse event signal for GLP-1s, yet it has generated essentially no regulatory response at the global health authority level. This creates a world where 43M+ Americans are on GLP-1s, the WHO has recommended broad global adoption, and no formal screening requirement for eating disorder history exists in prescribing guidance.

inbox/archive/health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md

@@ -0,0 +1,57 @@
+---
+type: source
+title: "Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes"
+author: "MDPI Nutrients (multiple authors)"
+url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12694361/
+date: 2025-11-01
+domain: health
+secondary_domains: []
+format: paper
+status: processed
+processed_by: vida
+processed_date: 2026-05-04
+priority: high
+tags: [glp1, eating-disorders, appetite, psychosocial, behavioral-health, anorexia, binge-eating]
+intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
+---
+
+## Content
+
+Review paper examining GLP-1 receptor agonists' effects on appetite regulation and eating disorder risk across different eating disorder subtypes. Published in MDPI Nutrients, archived on PMC (PMC12694361).
+
+Key findings:
+- GLP-1 RAs reduce hunger, increase satiety, dampen cravings, and influence food choice by activating brain regions controlling fullness and modulating reward circuits
+- Users typically experience smaller meals, longer eating intervals, and reduced emotional eating short-term — but these benefits may not persist long-term
+- Opposing mechanism paradox: beneficial for BED (reduces binge episodes via mesolimbic dopamine), potentially harmful for restrictive EDs (enhanced satiety reinforces restriction in vulnerable individuals)
+- Highest-risk populations: individuals with restrictive eating disorder histories (AN, atypical AN), those with high perfectionism or OCD traits, adolescents during critical development, racial/ethnic minorities facing intersectional stigma
+
+Clinical recommendations:
+1. Pre-treatment screening: SCOFF questionnaire for eating disorder history, compensatory behaviors, body image, and emotion regulation
+2. Ongoing monitoring: track eating behaviors, mood, and suicidal ideation; heightened vigilance during dose escalations
+3. Multidisciplinary approach: psychological care + dietitian + medical oversight (not standalone medication)
+4. Preventive strategies: introduce DBT/mindfulness BEFORE appetite suppression eliminates food-based coping
+5. Conclusion: GLP-1s "must be approached with caution: integrated into multidisciplinary care with rigorous monitoring" until long-term safety in diverse populations established
+
+Research gaps: "extremely limited" evidence on anorexia nervosa specifically; theoretical risks include appetite suppression masking restrictive behaviors, compulsive reliance on medication for control, reinforcement of maladaptive food rules
+
+## Agent Notes
+**Why this matters:** This is the most comprehensive review connecting GLP-1 pharmacology specifically to eating disorder risk by subtype — it operationalizes the paradox that the same mechanism (GLP-1R-mediated appetite suppression) is protective for BED and potentially harmful for AN. This is the mechanistic frame needed to interpret the VigiBase aROR 4.17-6.80 signal.
+
+**What surprised me:** The finding that benefits (smaller meals, reduced emotional eating) "may not persist long-term" — even for BED — suggests GLP-1 is not a durable behavioral treatment for any eating disorder subtype. This is consistent with the continuous-treatment dependency pattern established in earlier sessions for metabolic indications.
+
+**What I expected but didn't find:** Specific RCT evidence for GLP-1 in anorexia nervosa (AN) — the paper confirms this is essentially absent. The AN evidence base is entirely theoretical/mechanistic.
+
+**KB connections:**
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — eating disorder risk constrains behavioral health expansion
+- [[human-in-the-loop clinical AI degrades to worse-than-AI-alone]] — parallel to GLP-1 creating unintended behavioral consequences
+- [[behavioral primacy — health outcomes 80-90% determined by non-clinical factors]] — this paper argues behavioral risk factors (ED history, perfectionism) are the primary determinant of whether GLP-1 helps or harms
+
+**Extraction hints:** Multiple claim candidates: (1) GLP-1 eating disorder risk is subtype-specific — protective for BED, potentially harmful for restrictive EDs; (2) no RCT evidence for GLP-1 in AN exists despite pharmacovigilance signals; (3) pre-treatment ED screening is recommended but not required by any professional guideline or regulatory body
+
+**Context:** This is a broad narrative review, not an RCT or systematic review. Useful for the mechanistic argument but not primary evidence.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: Mechanistic framework for interpreting the pharmacovigilance eating disorder signal — explains WHY the signal exists via subtype-specific GLP-1R mechanism
+EXTRACTION HINT: Focus on the BED-protective vs. AN-harmful mechanism distinction; extractor should NOT collapse eating disorders into a single category

inbox/archive/health/2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap.md

@@ -7,10 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: official-guidance
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-04
 priority: medium
 tags: [glp1, who, guideline, obesity, global, eating-disorders, regulatory-gap]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content